You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德A股升停,H股升16%,派特別息+收入指引向好
格隆匯 03-18 10:05
藥明康德A股升停報70.43元,創2024年1月以來新高;H股一度升超16%報76港元,亦創2024年1月以來新高。藥明康德昨晚公佈業績顯示,雖然2024年全年收入和經調整溢利同比下降,但宣佈派末股息每股98.169分,以及派特別股息每股35分,共1.33169元,而去年同期派末期息每股99分。此外,藥明康德2024年營收實現環比三連增,第四季度收入更是增至115.4億元,強勢突破22年第四季度創下的單季度營收峯值。藥明康德預期2025年持續經營業務收入重回雙位數增長,增幅介乎10%-15%,而整體收入將達415至430億元。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account